利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.025 秒)

    Combination particles for the treatment of asthma
    1.
    发明授权
    Combination particles for the treatment of asthma 有权
    用于治疗哮喘的组合颗粒

    公开(公告)号：US07172752B2

    公开(公告)日：2007-02-06

    申请号：US10398381

    申请日：2001-10-05

    申请人： Wiwik Watanabe ,  Esko Kauppinen ,  Petri Ahonen ,  David Brown ,  Esa Muttonen

    发明人： Wiwik Watanabe ,  Esko Kauppinen ,  Petri Ahonen ,  David Brown ,  Esa Muttonen

    IPC分类号： A61K9/14 ,  A61K9/12 ,  A61K31/56

    CPC分类号： A61K9/0075 ,  A61K31/57 ,  Y10S514/826 ,  A61K31/165 ,  A61K2300/00

    摘要： Inhalation particles incorporating, in an individual particle, a combination of a βhd 2-agonist and a glucocorticosteroid in a predetermined and constant ratio, a process for the preparation thereof and pharmaceutical compositions comprising the inhalation particles. The particles have a narrow particle size distribution and are preferably in the form of spherical crystalline particles with a rough surface. The particles are particularly useful in the treatment of asthma and other respiratory disorders.

    摘要翻译： 吸入颗粒在单个颗粒中以预定和恒定的比例结合β-胡萝卜素2-激动剂和糖皮质激素的组合，其制备方法和包含吸入颗粒的药物组合物。 颗粒具有窄的粒度分布，并且优选具有粗糙表面的球形结晶颗粒的形式。 这些颗粒特别适用于治疗哮喘和其他呼吸系统疾病。

    Dry powder inhaler
    4.
    发明授权
    Dry powder inhaler 有权
    干粉吸入器

    公开(公告)号：US06983748B2

    公开(公告)日：2006-01-10

    申请号：US10399913

    申请日：2001-10-26

    申请人： David Brown ,  Esko Kauppinen ,  Juha Kurkela ,  Wiwik Watanabe ,  Jorma Jokiniemi ,  Esa Muttonen

    发明人： David Brown ,  Esko Kauppinen ,  Juha Kurkela ,  Wiwik Watanabe ,  Jorma Jokiniemi ,  Esa Muttonen

    IPC分类号： A61M15/00

    CPC分类号： A61M15/0065 ,  A61M2202/064 ,  A61M2206/14

    摘要： A device for delivering a powdered medicament by inhalation comprises an air inlet passage having low pressure-drop and low turbulence for stabilizing air flow before aerosolization, a dosing cup in the region of reduced air velocity to delay aerosolization, a high pressure drop throat to generate a high velocity flow, a rapidly expanding diverging passage to create a free jet of air with high turbulence and an outlet passage having large cross-sectional area to control the rate of dissipation of the free jet. The device is simple yet capable of consistently providing uniform and effective powder aerosolization and deagglomeration over a variety of patient inhalation profiles.

    摘要翻译： 用于通过吸入输送粉末药物的装置包括空气入口通道，其具有低压降和低湍流，用于在气雾化之前稳定空气流，在减小空气速度的区域中的计量杯以延迟气雾化，产生高压降喉 高速流动，快速扩张的扩张通道以产生具有高湍流的空气的自由射流和具有大横截面面积的出口通道以控制自由射流的耗散速率。 该装置简单，但能够持续提供均匀有效的粉雾雾化和各种患者吸入曲线上的解聚。

    Corticosteroid particles and method of production
    7.
    发明授权
    Corticosteroid particles and method of production 失效
    皮质类固醇颗粒和生产方法

    公开(公告)号：US08574630B2

    公开(公告)日：2013-11-05

    申请号：US13237792

    申请日：2011-09-20

    申请人： Libo Wu ,  Wiwik Watanabe ,  Jian Zhang

    发明人： Libo Wu ,  Wiwik Watanabe ,  Jian Zhang

    IPC分类号： A61K9/14 ,  A61K31/58 ,  C07J71/00

    CPC分类号： A61K9/0078 ,  A61K9/14 ,  A61K31/58 ,  A61K47/26 ,  Y10T428/2982

    摘要： A new particle morphology of glucocorticosteroids is described. The forms have a particle morphology that is particularly well suited for use in an inhaled corticosteroid drug suspension formulation for delivery from a next generation nebulizer device. Use of the new glucocorticosteroid particles enables enhanced drug delivery efficiency and increased residence time of the delivered drug in the lungs. New methods for producing glucocorticosteroid particles having these specific particle morphologies are also described. The methods provide a simplified, reproducible and scalable particle formation process that can produce glucocorticosteroid particles having a narrow particle size and shape distribution, a low surface energy, a low aspect ratio, uniform particle morphology and a reduced specific surface area.

    摘要翻译： 描述了糖皮质激素的新的颗粒形态。 这些形式具有特别适合用于从下一代雾化器装置递送的吸入皮质类固醇药物悬浮液制剂中的颗粒形态。 使用新的糖皮质激素颗粒使得能够提高药物递送效率并增加递送的药物在肺中的停留时间。 还描述了产生具有这些特定颗粒形态的糖皮质激素颗粒的新方法。 该方法提供了一种简化的，可重现的和可伸缩的颗粒形成过程，其可以产生具有窄粒度和形状分布，低表面能，低纵横比，均匀颗粒形态和降低的比表面积的糖皮质激素颗粒。

    FORMULATIONS FOR ALTERATION OF BIOPHYSICAL PROPERTIES OF MUCOSAL LINING
    8.
    发明申请
    FORMULATIONS FOR ALTERATION OF BIOPHYSICAL PROPERTIES OF MUCOSAL LINING 审中-公开
    用于改变粘膜内衬生物学特性的配方

    公开(公告)号：US20070053844A1

    公开(公告)日：2007-03-08

    申请号：US11419165

    申请日：2006-05-18

    申请人： Wiwik Watanabe ,  Matthew Thomas ,  Jeffrey Katstra ,  Robert Clarke

    发明人： Wiwik Watanabe ,  Matthew Thomas ,  Jeffrey Katstra ,  Robert Clarke

    IPC分类号： A61K48/00 ,  A61K9/14 ,  A61L9/04

    CPC分类号： A61K33/14 ,  A61K9/0014 ,  A61K9/0034 ,  A61K9/0043 ,  A61K9/0048 ,  A61K9/007 ,  A61K9/0078 ,  A61K31/255 ,  A61K31/721 ,  A61K47/02 ,  A61K47/12 ,  Y02A50/475

    摘要： Conductive formulations containing conductive agents, such as salts, ionic surfactants, or other substances that are in an ionized state or easily ionized in an aqueous or organic solvent environment, and methods of use, have been developed. One or more active agents, such as antivirals, antimicrobials, anti-inflammatories, proteins or peptides, may optionally be included with the formulation. The active agent may be administered with or incorporated into the formulation, or may be administered after the conductive formulation is administered. When applied to mucosal lining fluids, the formulation alters the physical properties such as the surface tension, surface elasticity, and bulk viscosity of the mucosal lining. The formulation is administered in an amount sufficient to alter biophysical properties in the mucosal linings of the body. The formulations may be administered for several different purposes: reducing the spreading of infectious diseases, both viral and bacterial, such as SARS, influenza, tuberculosis, and RSV in humans and hoof and mouth disease in cloven-tooted animals; minimizing ambient contamination due to particle formation during breathing, coughing, sneezing, or talking which is particularly important in the clean room applications; decreasing or preventing the occurrence of obstructive sleep apnea and some cases of irritable bowel syndrome; and controlling the uptake kinetics of drug molecules and pathogens.

    摘要翻译： 已经开发了含有导电剂，例如盐，离子表面活性剂或处于电离状态或容易在水溶液或有机溶剂环境中离子化的其它物质的导电配方，以及使用方法。 制剂中可以任选地包括一种或多种活性剂，例如抗病毒剂，抗微生物剂，抗炎剂，蛋白质或肽。 活性剂可以与制剂一起施用或掺入制剂中，或者可以在施用导电制剂后施用。 当施用于粘膜衬里液时，制剂会改变物理性质，如粘膜内衬的表面张力，表面弹性和体积粘度。 该制剂的施用量足以改变身体粘膜内衬的生物物理性质。 制剂可以用于几种不同的目的：减少感染性疾病，包括病毒和细菌，如SARS，流行性感冒，结核病和RSV在人类和蹄和口腔疾病的蔓延的动物; 在洁净室应用中特别重要的是在呼吸，咳嗽，打喷嚏或说话期间由于颗粒形成造成的环境污染最小化; 减少或预防阻塞性睡眠呼吸暂停和一些肠易激综合征的发生; 并控制药物分子和病原体的吸收动力学。

    Ultrasonic Aerosol Generator
    9.
    发明申请
    Ultrasonic Aerosol Generator 审中-公开
    超声波气溶胶发生器

    公开(公告)号：US20060249144A1

    公开(公告)日：2006-11-09

    申请号：US11381952

    申请日：2006-05-05

    申请人： Wesley DeHaan ,  Wiwik Watanabe

    发明人： Wesley DeHaan ,  Wiwik Watanabe

    IPC分类号： A61M11/00

    CPC分类号： B05B17/0615 ,  A61M15/0085

    摘要： An ultrasonic aerosol generator for delivering a liquid formulation in an aerosolized form at a high output rate of greater than 0.5 mL/minute, preferably greater than 1.0 mL/minute, and with diameters in a respirable size range, methods of using this device and kits including the device are described herein. The ultrasonic aerosol generator (10) contains at least (a) a liquid reservoir/aerosolization chamber (11), (b) a piezoelectric engine (12), (c) a relief aperture (13), and (d) an aerosol delivery element (20). Preferably the aerosolized particles that are delivered to the user through the aerosol delivery element have an average aerodynamic diameter of between 1 and 20 μm, more preferably between 1 and 10 μm, and most preferably between 1 and 5 μm. Optionally, the ultrasonic aerosol generator is designed to deliver more than one formulation simultaneously, preferably a low cost and/or stable formulation is administered simultaneously with a more expensive and/or labile formulation. In the preferred embodiment, the ultrasonic aerosol generator is a hand-held device designed for a single user.

    摘要翻译： 一种用于以大于0.5mL /分钟，优选大于1.0mL /分钟的高输出速率和具有可呼吸尺寸范围的直径的雾化形式的液体制剂输送超声波气雾发生器，使用该装置和试剂盒的方法 包括本文所述的装置。 超声波气溶胶发生器（10）至少包含（a）液体储存器/雾化室（11），（b）压电发动机（12），（c）释放孔（13），和（d） 元件（20）。 优选地，通过气溶胶输送元件输送给使用者的雾化颗粒的平均空气动力学直径为1至20μm，更优选为1至10μm，最优选为1至5μm。 任选地，超声气溶胶发生器被设计成同时递送多于一种制剂，优选地，与更昂贵和/或不稳定的制剂同时施用低成本和/或稳定的制剂。 在优选实施例中，超声波气溶胶发生器是为单个用户设计的手持式装置。